Bionano Genomics, Inc.

BNGO

US09075F3055

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.7861 ^USD	+3.57%		+4.81%	-58.41%

Apr. 17	Bionano Genomics, Hangzhou Diagens Biotechnology to Commercialize Cytogenetic Workflow for Reproductive Health	MT
Apr. 17	Bionano Genomics, Inc. and Hangzhou Diagens Biotechnology Co., Ltd. Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis That Combines OGM and Artificial Intelligence	CI

Bionano Genomics, Inc. Reports Goodwill Impairment for the Three Months Ended September 30, 2023

November 08, 2023 at 04:01 pm EST

Bionano Genomics, Inc. reported Goodwill Impairment for the Three Months Ended September 30, 2023. For the period, the company reported Goodwill Impairment of $77,280,000.

Latest news about Bionano Genomics, Inc.

Bionano Genomics, Hangzhou Diagens Biotechnology to Commercialize Cytogenetic Workflow for Reproductive Health	Apr. 17	MT
Bionano Genomics, Inc. and Hangzhou Diagens Biotechnology Co., Ltd. Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis That Combines OGM and Artificial Intelligence	Apr. 17	CI
Bionano Announces Publication Showing That Ogm Identifies Genetic Aberrations in Sarcoma Samples That May Lead to Improved Diagnosis But Were Missed by Classical Cytogenetics	Apr. 03	CI
Bionano Genomics, Inc. Announces Nine Poster Presentations and Introduces New High Throughput Stratys System at American Association for Cancer Research Annual Meeting	Apr. 02	CI
Bionano Genomics, Inc. Announces Publication of Breast Cancer Study Showing the Number of SVs Detected with OGM May be Related to Prognosis, Tumor Progression and Chemotherapy Resistance	Mar. 19	CI
Scotiabank Trims Price Target on Bionano Genomics to $6 From $7, Maintains Sector Outperform Rating	Mar. 07	MT
Bionano Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Transcript : Bionano Genomics, Inc., Q4 2023 Earnings Call, Mar 05, 2024	Mar. 05
Bionano Genomics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 05	CI
Bionano Genomics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	Mar. 05	CI
Bionano Genomics, Inc. announced that it has received $35 million in funding	Feb. 26	CI
Bionano Genomics, Inc. Announces Publication of A Study That Applied Ogm to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer	Jan. 25	CI
Bionano Announces Full Commercial Release of the Stratys?? System for High Throughput Optical Genome Mapping	Jan. 23	CI
Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care in Genetic Disease Testing	Jan. 11	CI
Bionano Genomics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	Jan. 08	CI
Bionano Announces Significant Upgrades to Its Bionano Solve Pipeline and Its Via? Software for Ogm Data Analysis in Constitution Genetic Disease Research	Dec. 28	CI
Bionano Genomics, Inc. Announces Publication of Largest Prospective Prenatal Study Comparing Ogm to Chromosomal Microarray Analysis and Karyotyping	Dec. 26	CI
North American Morning Briefing : Caution -2-	Nov. 14	DJ
Transcript : Bionano Genomics, Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Bionano Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Bionano Genomics, Inc. Reports Goodwill Impairment for the Three Months Ended September 30, 2023	Nov. 08	CI
Bionano Genomics, Inc. Reiterates Revenue Guidance for the Full Year 2023	Nov. 08	CI
Maxim Group Adjusts Bionano Genomics Price Target to $6 From $30, Maintains Buy Rating	23-10-18	MT
Bionano Genomics Expects $80 Million in Gross Proceeds From Registered Offering, Private Placement	23-10-11	MT
Bionano Genomics, Inc. Revises Revenue Guidance for the Third Quarter Ended September 30, 2023	23-10-11	CI

Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Bionano Genomics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.7861 USD

Average target price

6.667 USD

Spread / Average Target

+748.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
BIONANO GENOMICS, INC.	-58.41%	48.13M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B
RESMED, INC.	+26.76%	32.03B

Other Advanced Medical Equipment & Technology